Piramal: $53m Ash Stevens addition ‘synergistic’ with ADC business
The acquisition of Ash Stevens and a US high potent API facility will bolster Piramal’s antibody-drug conjugate offerings, the Indian CDMO says.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs